NCT05593250

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate the Efficacy and Safety of SHR-1905 in Subjects With Severe Uncontrolled Asthma.

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 260 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	SHR-1905	subcutaneous
DRUG	placebo	subcutaneous ,placebo

Timeline

• Start date: 2023-01-17
• Primary completion: 2025-04-30
• Completion: 2025-04-30
• First posted: 2022-10-25
• Last updated: 2025-01-27

Locations

1 site across 1 country: China